

Vishnu Chemicals (VCL) completed the acquisition of the chrome ore mine for ~USD10mn on a debt-free, cash-free, and liability-free basis on 21-Nov-25. VCL's wholly owned subsidiary would own 74% of the mining entity and 100% of the chrome beneficiation plant, along with mining and infrastructure assets. The chrome mine is spread over ~1,800 hectares and has >10mmt of reserves. Post-beneficiation, the actual usable chrome ore would be ~5.5-6mmt, which can last 50Y (ie basis VCL's current demand). With further expansion in chromium chemicals, VCL estimates the life of the reserve at 30Y. We expect it to benefit from a) integrated sourcing and manufacturing, b) stable supply of chemical-grade chrome ore without price volatility, and c) a faster ramp-up of the acquired plant. We expect annual EBITDA improvement of Rs300-400mn (basis current chrome ore prices) at optimal utilization, which will help meet VCL's annual chrome ore requirement. We retain BUY with an unchanged TP of Rs650 (20x Dec-27E EPS).

Chrome ore mine's acquisition – a key trigger for margin improvement

VCL began to backward integrate in FY21 which reduced the cost of manufacturing SDC and external dependence on key raw materials. VCL also acquired Ramadas Minerals in FY24 which has a barite beneficiation plant, to manufacture barium chemicals. The completion of acquisition of the chrome mine and beneficiation plant in South Africa will ensure supply security and reduce cost of chrome ore (thus, improving margins). The company has invested ~USD10mn on a debt-free, cash-free, and liability-free basis. The chrome mine is spread over ~1,800 hectares and has >10mmt of reserves. Post-beneficiation, the actual usable chrome ore would be ~5.5-6mmt, which can last 50Y (ie basis VCL's current demand). With further expansion in chromium chemicals, VCL estimates the life of the reserve at 30Y. Per our channel checks, the average cost of mining chrome ore, with transportation cost from South Africa to the plant in India, is ~USD250/mt. We believe this acquisition will lead to significant optionality benefit for VCL, in terms of gross margin, eventually leading to better EBITDA margins. We expect cost-savings of Rs300-400mn (basis current chrome ore prices) at optimal utilization, which will help meet VCL's annual chrome ore requirement. Thus, we build EBITDA CAGR of ~20% over FY25-28E, compared to revenue CAGR of ~11%.

Strontium carbonate plant commissioned in Q2FY26

Vishnu incurred capex of ~Rs825mn in H1FY26 (FY25: Rs880mn). We believe the amount was primarily spent on the strontium carbonate project (12,000mtpa) and on regular plant maintenance. The company commissioned the plant in Q2FY26; it expects commercial sales to start in the current quarter (ramp-up in CY26). Strontium carbonate is a cost-effective alternative to permanent magnets (ferrite magnets). It is also used in electronics, advanced ceramics, and metallurgy industries. Asia Pacific accounts for 50% of the strontium carbonate demand, followed by the EU and the US. We believe the company will primarily focus on import substitution and subsequently exports.

Vishnu Chemicals: Financial Snapshot (Consolidated)

Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	12,126	14,466	15,552	17,924	19,710
EBITDA	2,016	2,284	2,503	3,270	3,954
Adj. PAT	1,011	1,266	1,329	1,848	2,346
Adj. EPS (Rs)	15.4	18.8	19.7	27.5	34.9
EBITDA margin (%)	16.6	15.8	16.1	18.2	20.1
EBITDA growth (%)	(12.1)	13.3	9.6	30.6	20.9
Adj. EPS growth (%)	(32.4)	21.9	5.0	39.1	26.9
RoE (%)	18.1	15.6	13.4	16.0	17.2
RoIC (%)	13.2	12.5	11.3	13.4	14.9
P/E (x)	32.6	26.7	25.4	18.3	14.4
EV/EBITDA (x)	17.9	15.8	14.4	11.0	9.1
P/B (x)	4.7	3.6	3.2	2.7	2.3
FCFF yield (%)	(1.5)	(1.9)	(0.7)	2.0	1.4

Source: Company, Emkay Research

Target Price – 12M	Dec-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	29.5

Stock Data	VCL IN
52-week High (Rs)	596
52-week Low (Rs)	336
Shares outstanding (mn)	67.3
Market-cap (Rs bn)	34
Market-cap (USD mn)	379
Net-debt, FY26E (Rs mn)	3,920.1
ADTV-3M (mn shares)	0.2
ADTV-3M (Rs mn)	53.1
ADTV-3M (USD mn)	0.6
Free float (%)	30.8
Nifty-50	25,959.5
INR/USD	89.2


Shareholding, Sep-25

Promoters (%)	69.2
FPIs/MFs (%)	2.2/5.6

Price Performance

(%)	1M	3M	12M
Absolute	2.7	(3.1)	25.6
Rel. to Nifty	2.1	(7.1)	15.7

1-Year share price trend (Rs)




Meet Vora


meet.vora@emkayglobal.com
+91-22-66242474

Meet Gada


meet.gada@emkayglobal.com
+91-22-66121235

Exhibit 1: VCL's revenue CAGR is expected at 11% over FY25-28E


Source: Company, Emkay Research

Exhibit 2: VCL's EBITDA CAGR is expected at 20% over FY25-28E


Source: Company, Emkay Research

Exhibit 3: VCL is maintaining its asset turnover, along with growth capex

Source: Company, Emkay Research

Exhibit 4: VCL's capex to be largely funded through internal accruals and external debt

Source: Company, Emkay Research


Exhibit 5: Return ratios to improve, largely due to backward-integration benefits and volume improvement

Source: Company, Emkay Research


Exhibit 6: We cut our FY26/27/28E EPS by ~14%/9%/10% to factor in lower growth from Chromium business due to a delay in SDC expansion, partially offset by chrome ore's backward integration

Particulars (Rs mn)	FY26E			FY27E			FY28E		
	Revised	Earlier	Chg (%)	Revised	Earlier	Chg (%)	Revised	Earlier	Chg (%)
Revenue	15,552	16,823	(7.6)	17,924	19,234	(6.8)	19,710	21,114	(6.6)
EBITDA	2,503	2,861	(12.5)	3,270	3,547	(7.8)	3,954	4,353	(9.2)
EBITDA margin (%)	16.1	17.0	-92 bps	18.2	18.4	-20 bps	20.1	20.6	-56 bps
PAT	1,329	1,546	(14.0)	1,848	2,023	(8.6)	2,346	2,612	(10.2)
EPS (Rs)	19.7	23.0	(14.0)	27.5	30.0	(8.6)	34.9	38.8	(10.2)

Source: Company, Emkay Research

Exhibit 7: One-year forward P/E

Source: Company, Bloomberg, Emkay Research

Exhibit 8: One-year forward EV/EBITDA

Source: Company, Bloomberg, Emkay Research

Vishnu Chemicals: Consolidated Financials and Valuations

Profit & Loss					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	12,126	14,466	15,552	17,924	19,710
Revenue growth (%)	(13.9)	19.3	7.5	15.2	10.0
EBITDA	2,016	2,284	2,503	3,270	3,954
EBITDA growth (%)	(12.1)	13.3	9.6	30.6	20.9
Depreciation & Amortization	335	382	458	518	548
EBIT	1,680	1,902	2,045	2,752	3,406
EBIT growth (%)	(17.2)	13.2	7.5	34.6	23.8
Other operating income	-	-	-	-	-
Other income	125	153	187	197	207
Financial expense	367	373	460	485	485
PBT	1,437	1,682	1,772	2,464	3,128
Extraordinary items	0	0	0	0	0
Taxes	426	416	443	616	782
Minority interest	-	-	-	-	-
Income from JV/Associates	-	-	-	-	-
Reported PAT	1,011	1,266	1,329	1,848	2,346
PAT growth (%)	(25.8)	25.3	5.0	39.1	26.9
Adjusted PAT	1,011	1,266	1,329	1,848	2,346
Diluted EPS (Rs)	15.4	18.8	19.7	27.5	34.9
Diluted EPS growth (%)	(32.4)	21.9	5.0	39.1	26.9
DPS (Rs)	0.9	0.3	0	0	0
Dividend payout (%)	6.0	1.5	0	0	0
EBITDA margin (%)	16.6	15.8	16.1	18.2	20.1
EBIT margin (%)	13.9	13.1	13.1	15.4	17.3
Effective tax rate (%)	29.7	24.7	25.0	25.0	25.0
NOPLAT (pre-IndAS)	1,182	1,432	1,534	2,064	2,555
Shares outstanding (mn)	66	67	67	67	67

Source: Company, Emkay Research

Cash flows					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	1,313	1,529	1,585	2,267	2,921
Others (non-cash items)	44	103	0	0	0
Taxes paid	(305)	(412)	(443)	(616)	(782)
Change in NWC	(1,343)	(1,329)	187	(425)	(671)
Operating cash flow	675	902	2,247	2,230	2,501
Capital expenditure	(1,213)	(1,586)	(2,500)	(1,500)	(2,000)
Acquisition of business	(1)	-	0	0	0
Interest & dividend income	(378)	77	187	197	207
Investing cash flow	(1,539)	(996)	(2,313)	(1,303)	(1,793)
Equity raised/(repaid)	12	4	0	0	0
Debt raised/(repaid)	(633)	270	1,000	(500)	(500)
Payment of lease liabilities	0	0	0	0	0
Interest paid	(367)	(373)	(460)	(485)	(485)
Dividend paid (incl tax)	(61)	(20)	0	0	0
Others	1,930	217	-	0	-
Financing cash flow	881	98	540	(985)	(985)
Net chg in Cash	17	5	475	(58)	(276)
OCF	675	902	2,247	2,230	2,501
Adj. OCF (w/o NWC chg.)	2,018	2,232	2,060	2,654	3,172
FCFF	(538)	(684)	(253)	730	501
FCFE	(1,283)	(979)	(525)	442	224
OCF/EBITDA (%)	33.5	39.5	89.8	68.2	63.3
FCFE/PAT (%)	(126.9)	(77.3)	(39.5)	23.9	9.5
FCFF/NOPLAT (%)	(45.5)	(47.7)	(16.5)	35.3	19.6

Source: Company, Emkay Research

Balance Sheet					
Y/E March (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	131	135	135	135	135
Reserves & Surplus	6,881	9,133	10,462	12,310	14,657
Net worth	7,012	9,268	10,597	12,445	14,791
Minority interests	-	-	-	-	-
Non-current liab. & prov.	517	543	543	543	543
Total debt	3,153	3,423	4,423	3,923	3,423
Total liabilities & equity	10,682	13,233	15,563	16,911	18,757
Net tangible fixed assets	6,336	7,017	9,399	10,381	11,833
Net intangible assets	9	0	0	0	0
Net ROU assets	-	-	-	-	-
Capital WIP	158	691	350	350	350
Goodwill	9	0	0	0	0
Investments [JV/Associates]	3	3	3	3	3
Cash & equivalents	36	28	503	445	168
Current assets (ex-cash)	6,712	8,600	8,782	9,630	10,590
Current Liab. & Prov.	2,573	3,105	3,475	3,898	4,187
NWC (ex-cash)	4,140	5,495	5,307	5,732	6,403
Total assets	10,682	13,233	15,563	16,911	18,757
Net debt	3,117	3,395	3,920	3,478	3,255
Capital employed	10,682	13,233	15,563	16,911	18,757
Invested capital	10,485	12,511	14,707	16,113	18,236
BVPS (Rs)	107.0	137.7	157.4	184.9	219.7
Net Debt/Equity (x)	0.4	0.4	0.4	0.3	0.2
Net Debt/EBITDA (x)	1.5	1.5	1.6	1.1	0.8
Interest coverage (x)	4.9	5.5	4.9	6.1	7.5
RoCE (%)	19.9	18.0	16.1	18.8	20.9

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E March	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	32.6	26.7	25.4	18.3	14.4
EV/CE(x)	3.5	2.8	2.4	2.2	2.0
P/B (x)	4.7	3.6	3.2	2.7	2.3
EV/Sales (x)	3.0	2.5	2.3	2.0	1.8
EV/EBITDA (x)	17.9	15.8	14.4	11.0	9.1
EV/EBIT(x)	21.4	18.9	17.6	13.1	10.6
EV/IC (x)	3.4	2.9	2.5	2.2	2.0
FCFF yield (%)	(1.5)	(1.9)	(0.7)	2.0	1.4
FCFE yield (%)	(3.8)	(2.9)	(1.6)	1.3	0.7
Dividend yield (%)	0.2	0.1	0	0	0
DuPont-RoE split					
Net profit margin (%)	8.3	8.8	8.5	10.3	11.9
Total asset turnover (x)	1.3	1.2	1.1	1.1	1.1
Assets/Equity (x)	1.7	1.5	1.4	1.4	1.3
RoE (%)	18.1	15.6	13.4	16.0	17.2
DuPont-RoIC					
NOPLAT margin (%)	9.7	9.9	9.9	11.5	13.0
IC turnover (x)	1.4	1.3	1.1	1.2	1.1
RoIC (%)	13.2	12.5	11.3	13.4	14.9
Operating metrics					
Core NWC days	124.6	138.6	124.6	116.7	118.6
Total NWC days	124.6	138.6	124.6	116.7	118.6
Fixed asset turnover	1.4	1.4	1.3	1.3	1.2
Opex-to-revenue (%)	31.5	29.3	28.9	28.9	29.0


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Aug-25	476	650	Buy	Meet Vora
19-May-25	488	600	Buy	Meet Vora
06-Apr-25	419	600	Buy	Meet Vora
05-Feb-25	438	600	Buy	Meet Vora

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 24, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 24, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 24, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)